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However, in recent years, there has been an increasing number of reports of MBD in this population. 2 The increase has been attributed to a number of factors, such as the availability of new molecular biology methods to recover and identify mycobacteria, the increasing use of T-cell depletion techniques that may impair host defense recovery and the increasing number of SCT in countries in which the prevalence of tuberculosis is high. 3 Spain is a country with a high incidence of tuberculosis, which was estimated in 2003 as 28 cases per 10 5 inhabitants per year, 4 and NTM diseases have increased significantly in the last two decades. 5 De la Camara et al. 6 published in 2000 the results of a Spanish survey of tuberculosis after SCT in adult patients. They reported an incidence of 20 confirmed cases (eight autologous and twelve allogeneic transplants) among 8013 patients (0.249%), with a high mortality rate (55%). GVHD, corticosteroid treatment and TBI appeared to be associated with tuberculosis in allogeneic recipients.
We performed a retrospective study on the incidence of MBD among the pediatric patients (under 15 years of age) who underwent an SCT between 1984 and 2008 in the 12 centres belonging to GETMON (Spanish Working Party for Blood and Marrow Transplantation). Only patients with post-transplant MBD were included. The diagnosis of tuberculosis was considered certain if MT was cultured from a clinical sample and probable if acid-fast bacilli were seen on Ziehl-Neelse or Auramine-Rhodamine staining of tissue specimens from patients with clinical features suggestive of tuberculosis. To diagnose NTM disease, definitions from the Centers for Disease Control and Prevention (definite, probable, possible) as described by Weinstock et al. 7 were used. All patients who had received an autologous (n ¼ 1916) or allogeneic (n ¼ 1930) SCT were included. Nine cases of MBD were found, all from the allogeneic SCT group (Table 1) . Five patients had received a graft from related donors, two from unrelated donors and two from unrelated cord blood. All patients had been considered not at risk for mycobacterial infection at the pre-SCT visit, during which they were systematically questioned about familial exposure. They had not been vaccinated with BCG. Median age was 9 years (range 1-14) and there were seven males and two females. According to the above-mentioned criteria, MBD disease by MT was diagnosed in five cases (certain in four, probable in one). NTM disease was diagnosed in four (all definite); there were two cases of M. kansassi, one of M. abscessus and one of M. avium. Lung was the involved organ in eight patients and bowel in one.
The diagnosis of MBD was made at a median of 120 days (range 15-540 days) after SCT, and the median time interval between the first symptoms attributable to MBD and diagnosis was 39 days. All patients except one had a normal total neutrophil count at diagnosis. Differences in incidence of MBD between recipients of autologous or allogeneic SCT and among recipients of allogeneic SCT (that is, those who received SCT from related vs unrelated donors and related vs unrelated CB) were analyzed using the Fisher's exact test. The only statistically significant difference was observed between autologous and allogeneic SCT recipients (P ¼ 0.004). The same test was used to compare the incidence of MBD between conditioning regimens with or without TBI, malignant or non-malignant underlying disease, recipients of T-cell-depleted or notdepleted grafts, and patients with or without acute GVHD 42 and/or extensive chronic GVHD. There was a trend for a higher incidence of MBD in recipients of T-cell-depleted grafts (P ¼ 0.085). No other correlations were observed.
Patient characteristics, treatment and follow-up are summarized in Tables 2 and 3 . MT cases were treated with three to five drugs for 9-12 months. Three patients are alive and have been disease-free for more than 2 years. Two patients died from tuberculosis 1 month and 2 months, respectively, after diagnosis. Patients with non-tuberculous mycobacterial disease were treated with three to four drugs for 6-18 months. Three patients are alive and have been disease-free for 23, 90 and 96 months after diagnosis. One patient died from M. abscessus 2 months after diagnosis.
Our series shows that the risk of MBD is higher among recipients of allogeneic SCT as previously reported. 2, 3, 6 Tuberculosis is associated with a high mortality rate (40% in our series), mostly within 2 months of diagnosis, 6, 8 and delay of diagnosis from onset of symptoms is generally significant (39 days in our patients). This suggests that MT 
